This drug improves the course of MS by upregulating CD73, which converts adenosine monophosphate (AMP) to adenosine, an anti-inflammatory agent that helps prevent damage to MS-afflicted areas; it may be used as the first-line treatment for RRMS, active SPMS, and CIS. The gene discussed is NT5E; the disease is myeloid sarcoma.